Temporary antiretroviral treatment during primary HIV‐1 infection has a positive impact on health‐related quality of life: data from the Primo‐SHM cohort study
Objectives The aim of the study was to compare health‐related quality of life (HRQL) over 96 weeks in patients receiving no treatment or 24 or 60 weeks of combination antiretroviral therapy (cART) during primary HIV‐1 infection (PHI). Methods A multicentre prospective cohort study of PHI patients, w...
Gespeichert in:
| Veröffentlicht in: | HIV medicine 2012-11, Vol.13 (10), p.630-635 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 635 |
|---|---|
| container_issue | 10 |
| container_start_page | 630 |
| container_title | HIV medicine |
| container_volume | 13 |
| creator | Grijsen, ML Koster, GT Vonderen, MGA van Kasteren, M Kootstra, GJ Steingrover, R de Wolf, F Prins, JM Nieuwkerk, PT |
| description | Objectives
The aim of the study was to compare health‐related quality of life (HRQL) over 96 weeks in patients receiving no treatment or 24 or 60 weeks of combination antiretroviral therapy (cART) during primary HIV‐1 infection (PHI).
Methods
A multicentre prospective cohort study of PHI patients, with an embedded randomized trial, was carried out. HRQL was assessed with the Medical Outcomes Study Health Survey for HIV (MOS‐HIV) and a symptom checklist administered at weeks 0, 8, 24, 36, 48, 60, 72, 84 and 96. Mixed linear models were used for the analysis of differences in HRQL among the three groups.
Results
A total of 112 patients were included in the study: 28 received no treatment, 45 received 24 weeks of cART and 39 received 60 weeks of cART. Over 96 weeks of follow‐up, the groups receiving 24 and 60 weeks of cART had better cognitive functioning than the no‐treatment group (P = 0.005). Patients receiving 60 weeks of cART had less pain (P = 0.004), better role functioning (P = 0.001), better physical functioning (P = 0.02) and a better physical health summary score (P = 0.006) than the groups receiving no treatment or 24 weeks of cART. Mental health was better in patients receiving 24 weeks of cART than in patients in the no‐treatment group or the group receiving 60 weeks of cART (P = 0.02). At week 8, patients in the groups receiving 24 and 60 weeks of cART reported more nausea (P = 0.002), diarrhoea (P |
| doi_str_mv | 10.1111/j.1468-1293.2012.01020.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1125237738</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1125237738</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4020-f401fc00f17509ee538b015a18b9244bd582fe86ef9fcbd71f2e5ddb5b5c0b9c3</originalsourceid><addsrcrecordid>eNqNkc1u1DAQgCNERUvhFdAcuST4J94kSBxQVdhKRVRq4Wo59pj1KolT2yndG4_AS_BiPAlJd-m5c5mR5psZ2V-WASUFnePdtqDlqs4pa3jBCGUFoYSR4v5ZdvLYeP5Qlzlbrdhx9jLGLSG04g15kR0zJjgXZXmS_bnBfvRBhR2oIbmAKfg7F1QHKaBKPQ4JzBTc8APG4PqFW198__vrNwU3WNTJ-QE2KoKC0UeX3B2C60elEywNVF3azHTATiU0cDupzqUdeAuds_gejEoKbPA9pA3C1XzCz_j1-gtov_EhQUyT2b3KjqzqIr4-5NPs26fzm7N1fvn188XZx8tcl_P7c1sSajUhllaCNIiC1y2hQtG6bVhZtkbUzGK9QttY3ZqKWobCmFa0QpO20fw0e7vfOwZ_O2FMsndRY9epAf0UJaVMMF5VvJ7Reo_q4GMMaOXhfyQlcpEkt3JxIRcXcpEkHyTJ-3n0zeHK1PZoHgf_W5mBD3vgp-tw9-TFcjazVPwfBBymmQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1125237738</pqid></control><display><type>article</type><title>Temporary antiretroviral treatment during primary HIV‐1 infection has a positive impact on health‐related quality of life: data from the Primo‐SHM cohort study</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Wiley Free Content</source><source>IngentaConnect Free/Open Access Journals</source><creator>Grijsen, ML ; Koster, GT ; Vonderen, MGA ; van Kasteren, M ; Kootstra, GJ ; Steingrover, R ; de Wolf, F ; Prins, JM ; Nieuwkerk, PT</creator><creatorcontrib>Grijsen, ML ; Koster, GT ; Vonderen, MGA ; van Kasteren, M ; Kootstra, GJ ; Steingrover, R ; de Wolf, F ; Prins, JM ; Nieuwkerk, PT ; Primo-SHM study group ; the Primo‐SHM study group</creatorcontrib><description>Objectives
The aim of the study was to compare health‐related quality of life (HRQL) over 96 weeks in patients receiving no treatment or 24 or 60 weeks of combination antiretroviral therapy (cART) during primary HIV‐1 infection (PHI).
Methods
A multicentre prospective cohort study of PHI patients, with an embedded randomized trial, was carried out. HRQL was assessed with the Medical Outcomes Study Health Survey for HIV (MOS‐HIV) and a symptom checklist administered at weeks 0, 8, 24, 36, 48, 60, 72, 84 and 96. Mixed linear models were used for the analysis of differences in HRQL among the three groups.
Results
A total of 112 patients were included in the study: 28 received no treatment, 45 received 24 weeks of cART and 39 received 60 weeks of cART. Over 96 weeks of follow‐up, the groups receiving 24 and 60 weeks of cART had better cognitive functioning than the no‐treatment group (P = 0.005). Patients receiving 60 weeks of cART had less pain (P = 0.004), better role functioning (P = 0.001), better physical functioning (P = 0.02) and a better physical health summary score (P = 0.006) than the groups receiving no treatment or 24 weeks of cART. Mental health was better in patients receiving 24 weeks of cART than in patients in the no‐treatment group or the group receiving 60 weeks of cART (P = 0.02). At week 8, patients in the groups receiving 24 and 60 weeks of cART reported more nausea (P = 0.002), diarrhoea (P < 0.001), abdominal pain (P = 0.02), stomach pain (P = 0.049) and dizziness (P = 0.01) than those in the no‐treatment group. These differences had disappeared by week 24.
Conclusions
Temporary cART during PHI had a significant positive impact on patients’ HRQL as compared with no treatment, despite the initial, short‐term occurrence of more physical symptoms, probably related to drug toxicity.</description><identifier>ISSN: 1464-2662</identifier><identifier>EISSN: 1468-1293</identifier><identifier>DOI: 10.1111/j.1468-1293.2012.01020.x</identifier><identifier>PMID: 22533544</identifier><language>eng</language><publisher>England</publisher><subject>acute HIV infection ; Adolescent ; Adult ; Anti-HIV Agents - therapeutic use ; antiretroviral therapy ; Antiviral agents ; Check lists ; Clinical trials ; Cognitive ability ; Cohort Studies ; combination antiretroviral therapy ; Data processing ; Diarrhea ; Disease Progression ; Drug Administration Schedule ; Drugs ; Female ; Health Status ; health‐related quality of life ; HIV Seropositivity - drug therapy ; HIV-1 - drug effects ; Human immunodeficiency virus 1 ; Humans ; Infection ; Linear Models ; Male ; Mental disorders ; Middle Aged ; Nausea ; Pain ; primary HIV infection ; Prospective Studies ; Quality of Life ; Stomach ; Surveys and Questionnaires ; Time Factors ; Toxicity ; Viral Load ; Young Adult</subject><ispartof>HIV medicine, 2012-11, Vol.13 (10), p.630-635</ispartof><rights>2012 British HIV Association</rights><rights>2012 British HIV Association.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4020-f401fc00f17509ee538b015a18b9244bd582fe86ef9fcbd71f2e5ddb5b5c0b9c3</citedby><cites>FETCH-LOGICAL-c4020-f401fc00f17509ee538b015a18b9244bd582fe86ef9fcbd71f2e5ddb5b5c0b9c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1468-1293.2012.01020.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1468-1293.2012.01020.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,1427,27903,27904,45553,45554,46388,46812</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22533544$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Grijsen, ML</creatorcontrib><creatorcontrib>Koster, GT</creatorcontrib><creatorcontrib>Vonderen, MGA</creatorcontrib><creatorcontrib>van Kasteren, M</creatorcontrib><creatorcontrib>Kootstra, GJ</creatorcontrib><creatorcontrib>Steingrover, R</creatorcontrib><creatorcontrib>de Wolf, F</creatorcontrib><creatorcontrib>Prins, JM</creatorcontrib><creatorcontrib>Nieuwkerk, PT</creatorcontrib><creatorcontrib>Primo-SHM study group</creatorcontrib><creatorcontrib>the Primo‐SHM study group</creatorcontrib><title>Temporary antiretroviral treatment during primary HIV‐1 infection has a positive impact on health‐related quality of life: data from the Primo‐SHM cohort study</title><title>HIV medicine</title><addtitle>HIV Med</addtitle><description>Objectives
The aim of the study was to compare health‐related quality of life (HRQL) over 96 weeks in patients receiving no treatment or 24 or 60 weeks of combination antiretroviral therapy (cART) during primary HIV‐1 infection (PHI).
Methods
A multicentre prospective cohort study of PHI patients, with an embedded randomized trial, was carried out. HRQL was assessed with the Medical Outcomes Study Health Survey for HIV (MOS‐HIV) and a symptom checklist administered at weeks 0, 8, 24, 36, 48, 60, 72, 84 and 96. Mixed linear models were used for the analysis of differences in HRQL among the three groups.
Results
A total of 112 patients were included in the study: 28 received no treatment, 45 received 24 weeks of cART and 39 received 60 weeks of cART. Over 96 weeks of follow‐up, the groups receiving 24 and 60 weeks of cART had better cognitive functioning than the no‐treatment group (P = 0.005). Patients receiving 60 weeks of cART had less pain (P = 0.004), better role functioning (P = 0.001), better physical functioning (P = 0.02) and a better physical health summary score (P = 0.006) than the groups receiving no treatment or 24 weeks of cART. Mental health was better in patients receiving 24 weeks of cART than in patients in the no‐treatment group or the group receiving 60 weeks of cART (P = 0.02). At week 8, patients in the groups receiving 24 and 60 weeks of cART reported more nausea (P = 0.002), diarrhoea (P < 0.001), abdominal pain (P = 0.02), stomach pain (P = 0.049) and dizziness (P = 0.01) than those in the no‐treatment group. These differences had disappeared by week 24.
Conclusions
Temporary cART during PHI had a significant positive impact on patients’ HRQL as compared with no treatment, despite the initial, short‐term occurrence of more physical symptoms, probably related to drug toxicity.</description><subject>acute HIV infection</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Anti-HIV Agents - therapeutic use</subject><subject>antiretroviral therapy</subject><subject>Antiviral agents</subject><subject>Check lists</subject><subject>Clinical trials</subject><subject>Cognitive ability</subject><subject>Cohort Studies</subject><subject>combination antiretroviral therapy</subject><subject>Data processing</subject><subject>Diarrhea</subject><subject>Disease Progression</subject><subject>Drug Administration Schedule</subject><subject>Drugs</subject><subject>Female</subject><subject>Health Status</subject><subject>health‐related quality of life</subject><subject>HIV Seropositivity - drug therapy</subject><subject>HIV-1 - drug effects</subject><subject>Human immunodeficiency virus 1</subject><subject>Humans</subject><subject>Infection</subject><subject>Linear Models</subject><subject>Male</subject><subject>Mental disorders</subject><subject>Middle Aged</subject><subject>Nausea</subject><subject>Pain</subject><subject>primary HIV infection</subject><subject>Prospective Studies</subject><subject>Quality of Life</subject><subject>Stomach</subject><subject>Surveys and Questionnaires</subject><subject>Time Factors</subject><subject>Toxicity</subject><subject>Viral Load</subject><subject>Young Adult</subject><issn>1464-2662</issn><issn>1468-1293</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkc1u1DAQgCNERUvhFdAcuST4J94kSBxQVdhKRVRq4Wo59pj1KolT2yndG4_AS_BiPAlJd-m5c5mR5psZ2V-WASUFnePdtqDlqs4pa3jBCGUFoYSR4v5ZdvLYeP5Qlzlbrdhx9jLGLSG04g15kR0zJjgXZXmS_bnBfvRBhR2oIbmAKfg7F1QHKaBKPQ4JzBTc8APG4PqFW198__vrNwU3WNTJ-QE2KoKC0UeX3B2C60elEywNVF3azHTATiU0cDupzqUdeAuds_gejEoKbPA9pA3C1XzCz_j1-gtov_EhQUyT2b3KjqzqIr4-5NPs26fzm7N1fvn188XZx8tcl_P7c1sSajUhllaCNIiC1y2hQtG6bVhZtkbUzGK9QttY3ZqKWobCmFa0QpO20fw0e7vfOwZ_O2FMsndRY9epAf0UJaVMMF5VvJ7Reo_q4GMMaOXhfyQlcpEkt3JxIRcXcpEkHyTJ-3n0zeHK1PZoHgf_W5mBD3vgp-tw9-TFcjazVPwfBBymmQ</recordid><startdate>201211</startdate><enddate>201211</enddate><creator>Grijsen, ML</creator><creator>Koster, GT</creator><creator>Vonderen, MGA</creator><creator>van Kasteren, M</creator><creator>Kootstra, GJ</creator><creator>Steingrover, R</creator><creator>de Wolf, F</creator><creator>Prins, JM</creator><creator>Nieuwkerk, PT</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7U9</scope><scope>H94</scope></search><sort><creationdate>201211</creationdate><title>Temporary antiretroviral treatment during primary HIV‐1 infection has a positive impact on health‐related quality of life: data from the Primo‐SHM cohort study</title><author>Grijsen, ML ; Koster, GT ; Vonderen, MGA ; van Kasteren, M ; Kootstra, GJ ; Steingrover, R ; de Wolf, F ; Prins, JM ; Nieuwkerk, PT</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4020-f401fc00f17509ee538b015a18b9244bd582fe86ef9fcbd71f2e5ddb5b5c0b9c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>acute HIV infection</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Anti-HIV Agents - therapeutic use</topic><topic>antiretroviral therapy</topic><topic>Antiviral agents</topic><topic>Check lists</topic><topic>Clinical trials</topic><topic>Cognitive ability</topic><topic>Cohort Studies</topic><topic>combination antiretroviral therapy</topic><topic>Data processing</topic><topic>Diarrhea</topic><topic>Disease Progression</topic><topic>Drug Administration Schedule</topic><topic>Drugs</topic><topic>Female</topic><topic>Health Status</topic><topic>health‐related quality of life</topic><topic>HIV Seropositivity - drug therapy</topic><topic>HIV-1 - drug effects</topic><topic>Human immunodeficiency virus 1</topic><topic>Humans</topic><topic>Infection</topic><topic>Linear Models</topic><topic>Male</topic><topic>Mental disorders</topic><topic>Middle Aged</topic><topic>Nausea</topic><topic>Pain</topic><topic>primary HIV infection</topic><topic>Prospective Studies</topic><topic>Quality of Life</topic><topic>Stomach</topic><topic>Surveys and Questionnaires</topic><topic>Time Factors</topic><topic>Toxicity</topic><topic>Viral Load</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Grijsen, ML</creatorcontrib><creatorcontrib>Koster, GT</creatorcontrib><creatorcontrib>Vonderen, MGA</creatorcontrib><creatorcontrib>van Kasteren, M</creatorcontrib><creatorcontrib>Kootstra, GJ</creatorcontrib><creatorcontrib>Steingrover, R</creatorcontrib><creatorcontrib>de Wolf, F</creatorcontrib><creatorcontrib>Prins, JM</creatorcontrib><creatorcontrib>Nieuwkerk, PT</creatorcontrib><creatorcontrib>Primo-SHM study group</creatorcontrib><creatorcontrib>the Primo‐SHM study group</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>HIV medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Grijsen, ML</au><au>Koster, GT</au><au>Vonderen, MGA</au><au>van Kasteren, M</au><au>Kootstra, GJ</au><au>Steingrover, R</au><au>de Wolf, F</au><au>Prins, JM</au><au>Nieuwkerk, PT</au><aucorp>Primo-SHM study group</aucorp><aucorp>the Primo‐SHM study group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Temporary antiretroviral treatment during primary HIV‐1 infection has a positive impact on health‐related quality of life: data from the Primo‐SHM cohort study</atitle><jtitle>HIV medicine</jtitle><addtitle>HIV Med</addtitle><date>2012-11</date><risdate>2012</risdate><volume>13</volume><issue>10</issue><spage>630</spage><epage>635</epage><pages>630-635</pages><issn>1464-2662</issn><eissn>1468-1293</eissn><abstract>Objectives
The aim of the study was to compare health‐related quality of life (HRQL) over 96 weeks in patients receiving no treatment or 24 or 60 weeks of combination antiretroviral therapy (cART) during primary HIV‐1 infection (PHI).
Methods
A multicentre prospective cohort study of PHI patients, with an embedded randomized trial, was carried out. HRQL was assessed with the Medical Outcomes Study Health Survey for HIV (MOS‐HIV) and a symptom checklist administered at weeks 0, 8, 24, 36, 48, 60, 72, 84 and 96. Mixed linear models were used for the analysis of differences in HRQL among the three groups.
Results
A total of 112 patients were included in the study: 28 received no treatment, 45 received 24 weeks of cART and 39 received 60 weeks of cART. Over 96 weeks of follow‐up, the groups receiving 24 and 60 weeks of cART had better cognitive functioning than the no‐treatment group (P = 0.005). Patients receiving 60 weeks of cART had less pain (P = 0.004), better role functioning (P = 0.001), better physical functioning (P = 0.02) and a better physical health summary score (P = 0.006) than the groups receiving no treatment or 24 weeks of cART. Mental health was better in patients receiving 24 weeks of cART than in patients in the no‐treatment group or the group receiving 60 weeks of cART (P = 0.02). At week 8, patients in the groups receiving 24 and 60 weeks of cART reported more nausea (P = 0.002), diarrhoea (P < 0.001), abdominal pain (P = 0.02), stomach pain (P = 0.049) and dizziness (P = 0.01) than those in the no‐treatment group. These differences had disappeared by week 24.
Conclusions
Temporary cART during PHI had a significant positive impact on patients’ HRQL as compared with no treatment, despite the initial, short‐term occurrence of more physical symptoms, probably related to drug toxicity.</abstract><cop>England</cop><pmid>22533544</pmid><doi>10.1111/j.1468-1293.2012.01020.x</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1464-2662 |
| ispartof | HIV medicine, 2012-11, Vol.13 (10), p.630-635 |
| issn | 1464-2662 1468-1293 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1125237738 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Wiley Free Content; IngentaConnect Free/Open Access Journals |
| subjects | acute HIV infection Adolescent Adult Anti-HIV Agents - therapeutic use antiretroviral therapy Antiviral agents Check lists Clinical trials Cognitive ability Cohort Studies combination antiretroviral therapy Data processing Diarrhea Disease Progression Drug Administration Schedule Drugs Female Health Status health‐related quality of life HIV Seropositivity - drug therapy HIV-1 - drug effects Human immunodeficiency virus 1 Humans Infection Linear Models Male Mental disorders Middle Aged Nausea Pain primary HIV infection Prospective Studies Quality of Life Stomach Surveys and Questionnaires Time Factors Toxicity Viral Load Young Adult |
| title | Temporary antiretroviral treatment during primary HIV‐1 infection has a positive impact on health‐related quality of life: data from the Primo‐SHM cohort study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T03%3A32%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Temporary%20antiretroviral%20treatment%20during%20primary%20HIV%E2%80%901%20infection%20has%20a%20positive%20impact%20on%20health%E2%80%90related%20quality%20of%20life:%20data%20from%20the%20Primo%E2%80%90SHM%20cohort%20study&rft.jtitle=HIV%20medicine&rft.au=Grijsen,%20ML&rft.aucorp=Primo-SHM%20study%20group&rft.date=2012-11&rft.volume=13&rft.issue=10&rft.spage=630&rft.epage=635&rft.pages=630-635&rft.issn=1464-2662&rft.eissn=1468-1293&rft_id=info:doi/10.1111/j.1468-1293.2012.01020.x&rft_dat=%3Cproquest_cross%3E1125237738%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1125237738&rft_id=info:pmid/22533544&rfr_iscdi=true |